HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Another breakthrough has been with ADCs in combination with other treatments, such as an immunotherapy that inhibits the ...

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

It represents 82% of the ADC pipeline in major APAC markets. A surge in antibody-drug conjugates (ADCs) is driving China to ...

浩鼎(4174)旗下抗体药物复合体(Antibody-Drug Conjugate, ADC)抗癌新药OBI-992，已获「第11届世界ADC大奖」青睐，在超过1000个获提名者中，入围「2024 年最具潜力临床候选药物」；专家评审团将从获提名的八个候选药 ...

First Drug Is Expected To Be Available In Market By 2029 Says Kuick In Its ReportDelhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- ...

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the ...

Recent Studyt By Kuick highlights more than 600 Cancer Antibody Drug conjugates in Clinical TrialsDelhi, Sept. 19, 2024 ...

Kremlin says Lebanon pager blasts risk igniting tensions in 'explosive' region Merck, a leading science and technology company, launched the first single-use reactor specifically designed to ...